Phase 3 trial evaluates etrasimod's effect on ulcerative colitis symptoms, indicating its potential for moderate cases.
Introduction: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC).
No takes yet. Share an insight, caveat, or question.
Yarur et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: